Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transfusional Iron Overload”

51 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 51 results

Testing effectiveness (Phase 2)Study completedNCT00940602
What this trial is testing

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Who this might be right for
Myelodysplastic Syndromes
Novartis Pharmaceuticals 225
Post-approval studies (Phase 4)Ended earlyNCT02041299
What this trial is testing

Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias

Who this might be right for
Iron OverloadSickle Cell DiseaseOther Anemias
ApoPharma 230
Testing effectiveness (Phase 2)Study completedNCT00379483
What this trial is testing

Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload

Who this might be right for
Transfusional Iron Overload
Novartis Pharmaceuticals 66
Not applicableStudy completedNCT01376622
What this trial is testing

Changes in Pituitary Iron and Volume With Deferasirox

Who this might be right for
Iron Overload
Children's Hospital Los Angeles 130
Large-scale testing (Phase 3)Study completedNCT00469560
What this trial is testing

Safety, Tolerability, and Efficacy of Deferasirox in MDS

Who this might be right for
Myelodysplastic SyndromesHemosiderosis
Gruppo Italiano Malattie EMatologiche dell'Adulto 158
Testing effectiveness (Phase 2)Study completedNCT00600938
What this trial is testing

Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload

Who this might be right for
Transfusional Iron OverloadTransfusional Hemosiderosis
Novartis Pharmaceuticals 197
Testing effectiveness (Phase 2)Study completedNCT00390858
What this trial is testing

A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Who this might be right for
Transfusional Iron Overloadβ-thalassemia MajorPediatric Rare Anemia
Novartis Pharmaceuticals 40
Testing effectiveness (Phase 2)Study completedNCT01709032
What this trial is testing

Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia

Who this might be right for
Thalassemia Major With Severe Transfusional Iron Overload
Children's Hospital of Philadelphia 9
Testing effectiveness (Phase 2)Study completedNCT00067080
What this trial is testing

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

Who this might be right for
Anemia, Sickle Cell
Novartis Pharmaceuticals 195
Post-approval studies (Phase 4)Study completedNCT01250951
What this trial is testing

This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.

Who this might be right for
Myelodysplastic SyndromeThalassemia
Novartis Pharmaceuticals 111
Not applicableStudy completedNCT01394029
What this trial is testing

Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Who this might be right for
Transfusional Hemosiderosis
Novartis Pharmaceuticals 120
Large-scale testing (Phase 3)Study completedNCT00171210
What this trial is testing

An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload

Who this might be right for
Transfusional Iron Overload in β-thalassemia
Novartis Pharmaceuticals 506
Testing effectiveness (Phase 2)Study completedNCT00061763
What this trial is testing

Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias

Who this might be right for
Beta-thalassemiaMyelodysplastic SyndromesFanconi Syndrome+2 more
Novartis Pharmaceuticals 175
Testing effectiveness (Phase 2)Study completedNCT00395629
What this trial is testing

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Who this might be right for
Iron OverloadHereditary Hemochromatosis
Novartis Pharmaceuticals 49
Post-approval studies (Phase 4)Study completedNCT00171301
What this trial is testing

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

Who this might be right for
Beta-thalassemia MajorHemosiderosisIron Overload+1 more
Novartis Pharmaceuticals 233
Post-approval studies (Phase 4)Study completedNCT00117507
What this trial is testing

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Who this might be right for
Myelodysplastic SyndromesIron Overload
Novartis Pharmaceuticals 24
Post-approval studies (Phase 4)Study completedNCT00845871
What this trial is testing

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

Who this might be right for
Transfusional Hemosiderosis
Novartis Pharmaceuticals 65
Post-approval studies (Phase 4)Ended earlyNCT02443545
What this trial is testing

Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias

Who this might be right for
Iron OverloadSickle Cell DiseaseOther Anemias
ApoPharma 134
Not applicableStudy completedNCT00001203
What this trial is testing

Deferoxamine for the Treatment of Hemochromatosis

Who this might be right for
Diabetes MellitusHeart DiseaseHemochromatosis+1 more
National Heart, Lung, and Blood Institute (NHLBI) 151
Large-scale testing (Phase 3)Study completedNCT00061750
What this trial is testing

Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions

Who this might be right for
Beta-Thalassemia
Novartis Pharmaceuticals 595
Next Page